首页> 中文期刊> 《国际肝胆胰疾病杂志(英文版)》 >Targeted IL-24 gene therapy inhibits cancer recurrence after liver tumor resection by inducing tumor cell apoptosis in nude mice

Targeted IL-24 gene therapy inhibits cancer recurrence after liver tumor resection by inducing tumor cell apoptosis in nude mice

         

摘要

BACKGROUND:Interleukin-24 (IL-24) is a novel candi-date tumor suppressor that induces tumor cell apoptosis experimentally in a variety of human malignant cells including liver cancer cells. The present study was conducted to investigate the potential effect of recombinant adeno-associated virus (rAAV)-mediated IL-24 gene therapy on tumor recurrence and metastasis by inducing tumor cell apoptosis in a hepatocellular carcinoma (HCC) model in nude mice. METHODS:We established a recurrent and metastatic HCC model in nude mice and constructed an rAAV vector carrying alpha-fetoprotein (AFP) promoter for expressing the IL-24 gene (rAVV/AFP/IL-24). The vector was administered by regional injection (liver incisal margin). AFP was detected by radiation immunoassay. Histological evaluation of tumor recurrence and metastasis was performed for the liver and lung. The effect of tumor cell apoptosis was conifrmed by TUNEL analysis. RESULTS:IL-24 gene therapy prevented tumor recurrence and metastasis, as evidenced by marked decreases in the number of metastatic tumor nodules and tumor volume in the liver and lung. At the same time, serum AFP concentration decreased markedly in the IL-24 group compared with the control or rAAV groups (P<0.05). IL-24 gene therapy inhibited tumor recurrence and metastasis as evidenced by the induction of tumor cell apoptosis.CONCLUSION:The results demonstrated that targeted IL-24 gene therapy was effective in the prevention of postoperative recurrence and metastasis in an HCC nude mice model by induction of tumor cells apoptosis with potential minimum tumor burden.

著录项

  • 来源
    《国际肝胆胰疾病杂志(英文版)》 |2009年第002期|174-178|共5页
  • 作者单位

    Department of Hepatobiliary Surgery, Beijing Chaoyang Hospital, Capital Medical University, Beijing 100020, China Yang YJ, Chen DZ, Li LX, Sheng QS, Jin ZK and Zhao DF;

    Department of General Surgery, Beijing Chuiyangliu Hospital Beijing Minimaly Invasive Hospital, Beijing 100022, China Yang YJ;

    Department of Hepatobiliary Surgery, Beijing Chaoyang Hospital, Capital Medical University, Beijing 100020, China Yang YJ, Chen DZ, Li LX, Sheng QS, Jin ZK and Zhao DF;

    Department of General Surgery, Beijing Chuiyangliu Hospital Beijing Minimaly Invasive Hospital, Beijing 100022, China Yang YJ;

    Department of Hepatobiliary Surgery, Beijing Chaoyang Hospital, Capital Medical University, Beijing 100020, China Yang YJ, Chen DZ, Li LX, Sheng QS, Jin ZK and Zhao DF;

    Department of General Surgery, Beijing Chuiyangliu Hospital Beijing Minimaly Invasive Hospital, Beijing 100022, China Yang YJ;

    Department of Hepatobiliary Surgery, Beijing Chaoyang Hospital, Capital Medical University, Beijing 100020, China Yang YJ, Chen DZ, Li LX, Sheng QS, Jin ZK and Zhao DF;

    Department of General Surgery, Beijing Chuiyangliu Hospital Beijing Minimaly Invasive Hospital, Beijing 100022, China Yang YJ;

    Department of Hepatobiliary Surgery, Beijing Chaoyang Hospital, Capital Medical University, Beijing 100020, China Yang YJ, Chen DZ, Li LX, Sheng QS, Jin ZK and Zhao DF;

    Department of General Surgery, Beijing Chuiyangliu Hospital Beijing Minimaly Invasive Hospital, Beijing 100022, China Yang YJ;

    Department of Hepatobiliary Surgery, Beijing Chaoyang Hospital, Capital Medical University, Beijing 100020, China Yang YJ, Chen DZ, Li LX, Sheng QS, Jin ZK and Zhao DF;

    Department of General Surgery, Beijing Chuiyangliu Hospital Beijing Minimaly Invasive Hospital, Beijing 100022, China Yang YJ;

  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类
  • 关键词

获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号